CLINICAL TRIALS PROFILE FOR XPOVIO
✉ Email this page to a colleague
All Clinical Trials for xpovio
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01607905 ↗ | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | Karyopharm Therapeutics Inc | Phase 1 | 2012-06-18 | Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies. |
| NCT01607905 ↗ | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | Karyopharm Therapeutics, Inc | Phase 1 | 2012-06-18 | Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies. |
| NCT02025985 ↗ | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | Completed | Karyopharm Therapeutics Inc | Phase 2 | 2014-04-09 | The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in participants with advanced or metastatic gynaecological cancers by disease control rate (complete response (CR) or partial response (PR) or stable disease (SD) for at least 12 weeks, assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
| NCT02025985 ↗ | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | Completed | Karyopharm Therapeutics, Inc | Phase 2 | 2014-04-09 | The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in participants with advanced or metastatic gynaecological cancers by disease control rate (complete response (CR) or partial response (PR) or stable disease (SD) for at least 12 weeks, assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
| NCT02178436 ↗ | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | Recruiting | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2014-10-31 | This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as selinexor, gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. |
| NCT02178436 ↗ | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | Recruiting | Barbara Ann Karmanos Cancer Institute | Phase 1/Phase 2 | 2014-10-31 | This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as selinexor, gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. |
| NCT02323880 ↗ | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | Recruiting | National Cancer Institute (NCI) | Phase 1 | 2015-10-05 | This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or central nervous system (CNS) tumors that have come back (recurrent) or do not respond to treatment (refractory). Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for xpovio
Condition Name
Clinical Trial Locations for xpovio
Trials by Country
Clinical Trial Progress for xpovio
Clinical Trial Phase
Clinical Trial Sponsors for xpovio
Sponsor Name
